Kornimate/medical-research-clean huggingface dataset:
a randomized, controlled, multicenter trial of filgrastim (recombinant-methionyl human granulocyte colony stimulating factor; g-csf) for the prevention of grade 4 neutropenia in patients with hiv infection.

Conditions: HIV Infections; Cytopenias

Summary: to determine, in hiv-infected patients, the efficacy of filgrastim ( recombinant-methionyl human granulocyte-colony stimulating factor; g-csf ) in preventing grade 4 neutropenia, i.e., absolute neutrophil count (anc) \< 500 cells/mm3.

patients are randomized to receive subcutaneous g-csf at one of two different doses or no g-csf (observation) for 24 weeks. patients who experience anc \< 500 cells/mm3 on two consecutive occasions at least 24 hours apart prior to completing the 24-week study period will be considered to have reached the primary study endpoint; those in the observation group who reach the primary endpoint prior to week 24 may begin receiving g-csf for the remainder of the study period. after 24 weeks, patients may continue g-csf on a compassionate basis at the investigator's discretion.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * antiretroviral agents (e.g., azt, ganciclovir, ddi, ddc), trimethoprim-sulfamethoxazole (bactrim), interferon, and amphotericin b only if patient is on the same dose for at least 14 days prior to study entry (patients may not start or stop these agents within 14 days prior to study entry). patients must have: * documented hiv infection or history of aids. * cd4 count \< 200 cells/mm3. * anc (segmental neutrophils plus bands) \>= 750 and \< 1000 cells/mm3 within 7 days prior to study entry. * life expectancy of at least 6 months. note: * stable kaposi's sarcoma is permitted provided patient does not require myelosuppressive therapy (other than interferon) within 4 weeks prior to study entry. prior medication: allowed: * prior antiretroviral agents (e.g., azt, ganciclovir, ddi, ddc), trimethoprim-sulfamethoxazole (bactrim), interferon, and amphotericin b. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * malignancy other than kaposi's sarcoma and localized basal or squamous cell carcinoma. * psychiatric, addictive, or other disorder that compromises ability to give informed consent. * known hypersensitivity to e. coli-derived products. prior medication: excluded: * g-csf, other hematopoietic growth factors (except for erythropoietin), or investigational agents within 14 days prior to study entry. substance abuse that would compromise compliance.

Keywords: neutropenia granulocyte colony-stimulating factor acquired immunodeficiency syndrome
lead mobilization & bone turnover in pregnancy/lactation

Conditions: Lead Poisoning

Summary: we are examining the role of maternal bone lead turnover during pregnancy and lactation as a potential source of lead exposure for the fetus and the infant (via breast milk). a cohort, ascertained at entry to care, consists of \>1000 women to be followed through pregnancy. in the postpartum subjects are recruited for a nested case control study to assess the influence of lactation on maternal bone density, maternal blood lead and breast milk lead.


Eligibility criteria:
1. positive pregnancy test, age 12-35 and informed consent; 2. gestation \<28 weeks at entry to prenatal care; 3. no history of serious chronic or metabolic diseases, which could affect maternal growth or bone density; 4. not corticosteroid user or diagnosed use of illicit drugs; 5. eligible for lactation study: ascertainment during or participation in the pregnancy study and a negative pregnancy test.

Keywords: pregnancy lead exposure lactation bone mineralization maternal-fetal exchange
development of modified combined apgar scoring system for evaluation of infants in the delivery room

Conditions: Neonatal Respiratory Failure

Summary: apgar scoring system has been widely used for the evaluation of the infant's postnatal condition. as conventional apgar scoring system is affected by gestational age and resuscitative efforts, there is a need for development of new scoring systems for the assessment in the delivery room. herein, modified combined apgar scoring system which includes two new parameters (cord blood ph and targeted oxygen saturation level) has been developed and the utility of this modified system was compared with conventional and combined apgar scoring systems for prediction of hospitalization.

this is a prospective cohort study. conventional, combined and modified combined apgar scores at minutes 1 and 5 are all recorded. for modified scoring system, blood sample is obtained from the umbilical artery and pulse oximetry is used for measurement of oxygen saturation. prediction of nicu hospitalization is used as a surrogate parameter to compare the scores.

Eligibility criteria:
inclusion criteria: term neonates preterm neonates parental approval exclusion criteria : major congenital/chromosomal abnormalities lack of informed consent stillbirth outborn infants
rehabilitation after arthroscopic partial meniscectomy

Conditions: Knee Pain

Summary: water-based vs. land-based rehabilitation after arthroscopic partial meniscectomy in middle-aged active patients with a degenerative meniscal tear: a randomized, controlled study

in this study, we aimed to determine and compare the benefits of water-based exercise (wbe) and land-based exercise (lbe) on pain, functionality, and quality of life after arthroscopic partial meniscectomy (apm). middle-aged (35-50), active 30 patients having apm for a degenerative meniscal tear randomized into lbe (n=15) and wbe (n=15) groups. the pain level (visual analogue scale \[vas\]), isokinetic muscle strength, quality of life (short form-36 \[sf-36\]), and function level (single-leg hop test and lysholm questionnaire) were evaluated prior to treatment and at follow-up visits at the fourth and eighth week after surgery. the exercise sessions were conducted 3 times a week for 4 weeks in both groups.

Eligibility criteria:
inclusion criteria: the inclusion criteria comprised a non-locked painful knee of more than 1 month, age between 35-50 years, a clinical history and examination compatible with degenerative meniscus, positive findings of a degenerative meniscal tear visible with magnetic resonance imaging (mri), no response to nonoperative treatment of at least 3 months after onset of symptoms, and no evidence of advanced osteoarthritis (oa) on x-rays or mri exclusion criteria: the exclusion criteria employed were advanced knee oa, systemic inflammatory disease, a concurrent tear of posterior cruciate ligament, a concurrent collateral ligament repair, other problems causing knee pain (e.g., hip and ankle pathologies), a history of cardiopulmonary disease that could limit isokinetic and functional testing, an unstable medical condition, a serious cognitive deficit, a psychiatric problem, no capacity for independent walking and standing, an open wound on the skin, or pregnancy

Keywords: rehabilitation exercise aquatherapy
effect of olivomed (olive extract) on endothelial, cardiac and vascular function

Conditions: Coronary Artery Disease

Summary: olive extracts are considered to have antioxidant properties. the investigators will study the effect of olive extracts containing hydroxytyrosol (ht)-olivomed and combination of oleuropein (ol), hydroxytyrosol (ht), oleocanthal (oc) - olivomedsmart on endothelial, cardiac and vascular function in patients with coronary artery disease .

30 patients with stable angiographically documented coronary artery disease will be randomized to receive olive extracts with high concentration of hydroxytyrosol (5 mg po twice per day included in olivomed capsules) or placebo for one month and then they will be switched off to the alternate treatment (placebo or olivomed capsules) for another one month. 30 patients with stable angiographically documented coronary artery disease will be randomized to receive olivomedsmart - olive extracts with oleuropein (ol), hydroxytyrosol (ht), oleocanthal (oc) (ol:ht:oc 2:1:3) or placebo for one month and then they will be switched off to the alternate treatment (placebo or olivomed capsules) for another one month. the same quantity of hydroxytyrosol was contained in two supplements.

Eligibility criteria:
inclusion criteria: 1. age \<70 years 2. stable coronary heart disease 3. patients with acute coronary syndrome who have undergone percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg), 2 months must have passed since the incident 4. high ldl levels, low hdl, high triglycerides exclusion criteria: 1. age\> 70 years 2. patient with diabetes 3. patient with hypertension 4. patient with liver disease 5. patient with thyroid disease 6. patient with active malignancy 7. patient with a disease that affects inflammatory markers (rheumatic diseases, etc.) 8. patient with chronic renal failure (creatinine\> 2 mg / dl) 9. patient treated chronically with corticosteroids 10. patient who has joined a weight loss program or any dietary intervention or intensive exercise programme within the previous 2 months or consumes multivitamin preparations with antioxidant properties.

Keywords: olive oil, myocardial deformation, glycocalyx
vitamin d deficiency and effect of its supplementation on interstitial lung diseases(ild).

Conditions: Lung Diseases, Interstitial; Vitamin D Deficiency

Summary: this study evaluates serum level of vitamin d in interstitial lung diseases in patients with interstitial lung diseases other than connective tissue diseases associated-interstitial lung diseases and effects of its supplementation. all patients will receive the standard regimen of treatment (corticosteroids and immunosuppressive drugs)and will be randomly assigned to either group 1:who will receive vitamin d supplementation (interventional group)or group 2:who will not receive vitamin d supplementation(control group).

pulmonary fibrosis was due to chronic inflammation and disordered wound healing in response to damage induced by a variety of agents such as viral infection and radiotherapy or environmental toxins.it is characterized by accumulation of myofibroblasts and excessive deposition of the extracellular matrix.epithelial cells undergoes epithelial mesenchymal transition (emt). supplementation with vitamin d or its analogs suppresses lung fibrosis via triggering anti-fibrotic effect through attenuation of transforming growth factor beta (tgf-b).vitamin d can reduce tgf-b expression and attenuate tgf-b induced epithelial mesenchymal transition in lung fibroblast and epithelial cells.

Eligibility criteria:
inclusion criteria: patients who will be diagnosed as interstitial lung disease by multidisciplinary approach based on clinical, functional, radiological and pathological diagnosis when needed. exclusion criteria: * patients who have other diseases affecting vitamin d levels like chronic liver diseases, chronic kidney diseases and malignancy. * patients who will be unable to do pulmonary functions or 6-minutes walk test. * patients with ischemic heart diseases and congestive heart failure. * patients with connective tissue-associated interstitial lung diseases. * interstitial lung diseases exacerbation.

Keywords: interstitial lung diseases vitamin d deficiency
stent geometry in sutureless bioprosthetic valves

Conditions: Aortic Valve Stenosis; Heart Valve Diseases

Summary: a single-center prospective interventional trial. patients implanted with a sutureless bioprosthetic aortic valve at karolinska university hospital in stockholm, sweden from 2012 will be eligible. 4-dimensional volume-rendered computed tomography (ct) of the heart will be performed. the aim of the ct is to assess valve geometry and hypo-atrenuated leaflet thickening. results of the ct examination, preoperative clinical characteristics, and postoperative clinical data will be registered. data will be collected prospectively and retrospectively. informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures.


Eligibility criteria:
inclusion criteria: * implanted with a sutureless perceval (livanova) sutureless bioprosthetic aortic valve at karolinska university hospital in stockholm, sweden between 2012 and 2016 * provide written informed consent exclusion criteria: •contraindication for ct with intravenous contrast injection
lake washington vascular venaseal™ post-market evaluation (waves)

Conditions: Venous Reflux

Summary: the venaseal closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (gsv), through endovascular embolization with coaptation. venaseal is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (dus).


Eligibility criteria:
key inclusion criteria: * reflux in at least one target vein; * one or more of the following symptoms related to a tv: aching, throbbing, heaviness, fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort, swelling; * ceap classification of c2 (if symptomatic) through c5; key exclusion criteria: * current, regular use of systemic anticoagulation; * previous or suspected deep vein thrombosis or pulmonary embolus, or active acute superficial thrombophlebitis, or thrombophlebitis migrans; * previous treatment such as laser or radiofrequency ablation of venous disease in targeted vein segment; * known hypercoagulable disorder; * pregnant or breast feeding at enrollment; * known sensitivity to cyanoacrylate adhesives; * venous treatment in the contralateral limb within the last 30 days, or who require contralateral treatment within three months; * planned to undergo additional ipsilateral treatments on the same leg within 3 months following treatment.

Keywords: varicose veins great saphenous vein venous insufficiency
sodium awareness in lactation trial

Conditions: Breastfeeding; Preterm Birth; Breast Pumping; Lactation; Insufficient, Partial

Summary: salt is a multi-centre, non-blinded, non-randomized prospective interventional pilot study teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (na) using point-of-care (poc) meters. a drop in na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population. primary objective: establish feasibility, acceptance, and time cost of parent-led parent milk na testing in the first 14 days postpartum secondary objective: further investigate relationships between pumping behaviours, lactation risk factors, daily milk na and lactation outcomes exploratory objective: explore how poc na data may be used to modify pumping behaviour and milk volumes


Eligibility criteria:
inclusion criteria: 1. consent provided 2. have delivered a preterm singleton or twin infant at \<35 weeks gestation admitted to a study nicu at birth or transferred into a study nicu from another nicu within the first 72 hours postpartum 3. day 5 or less postpartum (day 1 = day of delivery) upon enrollment (ideally day 3 or less) 4. plans to lactate at least 2 weeks and initiate lactation with a breast pump 5. expected infant nicu stay of 7+ (ideally 14+) days in enrollment nicu(s) exclusion criteria: 1. potential study participant's infant is critically ill and not expected to survive or has lethal diagnosis with plans by medical team/family to redirect care 2. has delivered triplets or higher order multiples (potential confounder for lactation challenges; of note, triplets or higher are rare, on the order of a few parents annually) 3. lactation contraindication(s) (i.e., active chemotherapy) or declines lactation initiation 4. history of breast surgery that may affect ability to lactate (i.e., breast reduction; breast augmentation that utilized nipple incisions) 5. using or planning to use hormonal birth control in the first 14 days post-partum as may affect secretory activation/lactation 6. unable/unwilling to be present in study nicu during any of first 5 days postpartum 7. presumption by the medical team that infant will be in study nicu for \<5 days
osteoporosis associated vertebral fractures - medical and socio-economic aspects in austria

Conditions: Osteoporotic Fractures

Summary: the purposes of this study were to analyse demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.


Eligibility criteria:
inclusion criteria: -patients older than 50 years of age with vertebral fractures at the thoracic or lumbar spine caused by a low-energy trauma or without any trauma, or with vertebral fractures at the thoracic or lumbar spine with typical osteoporotic deformity of the vertebrae (wedge, fish, or flat) exclusion criteria: * patients younger than 50 years of age * vertebral fractures at the cervical spine * vertebral fractures at the thoracic or lumbar spine caused by a high-energy trauma (motor-vehicle accident, sports-related accident, fall from a considerable height) * patients suffering from a malignancy, making a pathological fracture presumably, patients with vertebral fractures, whose dataset of follow-up monitoring was lacking, to make an evaluation of osteoporotic involvement impossible
activity breaks for brain health in adolescents

Conditions: Healthy Adolescents

Summary: the main aim for this study is to investigate to what extent physical activity of moderate or low intensity, relative to prolonged inactivity, may acutely alter neural activity-related prefrontal cortex oxygenated hemoglobin during a cognitive demanding task in 13- 15 year-old adolescents. the study is primarily focused on investigating these effects in ecologically valid conditions, i.e. activity patterns that closely resemble a typical day in school and using activity modes that are suitable in a school setting.

the study will be a controlled crossover experimental trial with three conditions. each participant will complete each of the three experimental conditions, separated by a washout period of minimum four days. physical activity behaviours and sleep will be monitored the day/night before each test day. the first visit will be a familiarization session for the collection of demographic data, fitness testing, and acquaintance with experimental procedures. on the second, third, and fourth visits, participants will undergo three different standardized 80-minutes interventions in a randomized order. before and immediately after the 80-minutes interventions, blood pressure, augmentation index, and cerebral hemodynamic response of the prefrontal cortex during standardized cognitive tasks (nback test) will be measured. additionally, saliva samples will be collected the morning of the test day, and before and after the interventions.

Eligibility criteria:
exclusion criteria: * ongoing medication that can affect central circulation or brain circulation * ongoing infection * inability to apprehend information about the study or to perform the tests
ocular screening in children and young adults at risk for increased intracranial pressure

Conditions: Intracranial Pressure Increase

Summary: the purpose of this study is to evaluate the vision and posterior segment of eyes in children and young adults less than 22 years of age with risk, suspicion, or past medical history significant for elevated intracranial pressure (icp). patients will have visual acuity and color vision tested. assessment of the posterior segment will involve using a non-invasive (non-contact) imaging technique (i.e. a portable fundus camera in clinic and hospital settings).

the need for non-invasive evaluation of icp is an active area of study. the current gold standard is intraventricular or intraparenchymal catheters but these are invasive, expensive, and require sedation; and thus the need for an effective non-invasive screening tool. the utility of funduscopy in identifying processes affecting icp has long been recognized, i.e. papilledema, ocular venous engorgement, blurring of the optic disk. studies have demonstrated that funduscopy may have a role in the qualitative assessment of increased icp as a highly sensitive test. however, conventional bedside funduscopy does not allow for image capture and may necessitate pupillary dilation. portable fundus cameras address these issues, allowing image capture and storage and the potential for non-mydriatic imaging, i.e. imaging without dilation of eyes. and as demonstrated in a recent study, portable fundus cameras are efficient (median exam time was 3 minutes and 24 seconds in a pediatric emergency department). additionally, icp screening in asymptomatic patients remains limited. patients being treated with medications for acne, specifically tetracyclines (e.g. minocycline and doxycycline), retinol, and isotretinol, are at particular risk for increased icp but often are not identified until they are symptomatic (i.e. headaches, visual loss, papilledema). symptom onset has been documented from 2 weeks up to 1 year from drug initiation. the percentage of patients with subclinical asymptomatic disease is unclear. this study would allow us to describe the presence of subclinical disease in our population and the role/utility of routine non-invasive screening methods.

Eligibility criteria:
inclusion criteria: * capable and willing to provide consent * less than 22 years of age * history of or suspicion for elevated icp or starting/currently taking high-risk medications associated with increased risk for elevated icp exclusion criteria: * unable or unwilling to give consent * over 21 years of age

Keywords: vision screening portable fundus camera acne medication
mri-based artificial intelligence software (nns-sot) for onset time estimation in lesion with acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: this study evaluates the efficacy of investigational device named stroke onset time artificial intelligence(ai) (model name:nns-sot). using the investigational device, analyze the image and the onset time of occurrence of acute ischemic stroke lesion on the brain image (4.5 hours or more from the onset of symptoms) and evaluate the efficacy of correctly estimating the onset time.

this clinical trial software medical device (model name: nns-sot) is developed based on artificial intelligence algorithms. through clinical validation, it will be easier to determine whether the golden hour (4.5 hours) has elapsed at the time of cerebral infarction in the medical field. it can be used for estimation of the onset time of occurrence in acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * brain imaging in patients with acute ischemic stroke aged 20 years and older * brain imaging of ischemic stroke manifestation lesion confirmed by medical staff in brain mr image * brain imaging taken within 24 hours of ischemic stroke symptoms * brain imaging including magnetic resonance(mr) images (dwi and flair) * patients with clearly recorded onset time of acute ischemic stroke symptoms exclusion criteria: * brain imaging used in nns-sot development process * brain imaging with noise (artifact) * brain images damaged in data